FDAnews Drug Daily Bulletin

WESTAIM'S NUCRYST UNIT FILES FOR PUBLIC OFFERING

Dec. 5, 2005
A A

NUCRYST Pharmaceuticals, a wholly owned subsidiary of Westaim <WED.TO>, on Friday said that it was planning an initial public offering of 5.77 million common shares for between $12 and $14 per share. Excluding the sale of any over-allotment shares, Westaim will retain almost 65 percent of its stake in NUCRYST, which makes medical products that fight infections from a variety of wound types and inflammation.

Metro (http://www.metronews.ca/reuters_business.asp?id=112899)